Medpace Holdings, Inc. annual report, FY2021

Business context and reporting period

Medpace Holdings, Inc. filed this Form 10-K for the fiscal year ended December 31, 2021. It is a global contract research organization providing full-service Phase I–IV clinical development and related laboratory services to biotechnology, pharmaceutical, and medical-device companies. The company reported one operating segment and approximately 4,500 employees across 41 countries.

Financial performance and liquidity

Revenue growth was broad-based, led by Oncology, Metabolic, Central Nervous System, and other therapeutic areas. Total direct costs rose 25.8%, faster than revenue, reflecting higher reimbursed out-of-pocket expenses and personnel costs. The effective tax rate fell to 9.9% from 13.7%, primarily due to increased excess tax benefits from share-based compensation and FDII benefits.

Cash and cash equivalents were $461.3 million at year-end, versus $277.8 million a year earlier. The company had no borrowings under its $50 million unsecured revolving facility and reported $49.8 million available; it was in compliance with financial covenants. Capital expenditures were $28.3 million. Financing cash outflow included $62.1 million of share repurchases. No dividend was paid, and management said it did not plan cash dividends for the foreseeable future.

Material changes versus the prior comparable period

• Net new business awards increased to $1,610.4 million from $1,175.0 million.
• Backlog grew 29.5% to $1,997.1 million from $1,541.7 million. Management expected approximately $1.03–$1.05 billion of year-end backlog to convert to revenue during 2022; backlog is not a guaranteed revenue measure and contracts are generally terminable.
• Cash increased by $183.5 million during 2021, compared with a $145.8 million increase in 2020. Operating cash flow was broadly stable, while higher advanced billings contributed to cash generation.
• Share repurchases declined to $62.1 million from $98.3 million. The board added $300 million to the repurchase authorization in February 2022.

Outlook, commentary, risks, and unusual items

Management expected COVID-19 effects to be temporary, primarily involving restricted site access, slower patient enrollment, and delayed trial start-ups. It also stated that the pandemic had significantly adversely affected results and that the future financial impact could not be reasonably estimated. The filing provides no specific earnings or revenue guidance beyond the backlog conversion estimate.

• Customer cancellation, trial delays, limited sponsor funding, and slower backlog conversion can affect revenue and utilization. Small and mid-sized biopharmaceutical companies generated 93% of 2021 revenue (77% and 16%, respectively).
• Fixed-fee contracts and estimates of costs to complete expose margins to underpricing, cost overruns, and delayed or unapproved change orders. Revenue recognition estimates for clinical research contracts were identified as a critical audit matter.
• Other principal risks include hiring and retaining skilled staff, competition and pricing pressure, clinical-trial execution and patient safety, regulatory and privacy compliance, cybersecurity, international operations, and foreign exchange. A 10% adverse currency-rate movement was estimated to reduce 2021 pretax income by approximately $12.3 million.
• Related-party arrangements include leases of Cincinnati facilities from entities owned by the CEO and expenses for executive aviation and hotel services. The CEO controlled approximately 17.2% of outstanding shares at year-end and had significant influence over shareholder matters.
• Management said pending legal proceedings were not expected to have a material adverse effect. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting.

Important facts for investors to verify

1. Whether award growth and backlog convert into revenue at the expected pace, particularly the stated 2022 conversion range.
2. Whether operating margins stabilize as staffing and reimbursed trial costs rise; compare underlying service costs with pass-through expenses.
3. The extent and duration of COVID-related site, enrollment, and start-up disruption and its effect on sponsor funding and cancellations.
4. How much 2021 cash generation depended on advanced billings and whether collections and working capital remain favorable.
5. The terms, governance, and financial implications of related-party leases and other arrangements, as well as the expanded share-repurchase authorization.